BIO — Bio-Rad Laboratories, Inc.

Is BIO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Overbought As of August 19, 2026

Bio-Rad Laboratories, Inc. (BIO) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $364.26. The rating moved from Neutral to Overbought on August 6, 2026.

See all overbought Healthcare stocks →

AI analysis

Bio-Rad Laboratories, Inc. (BIO) benefits from durable demand for life-science tools and diagnostics, with recurring consumable revenue providing margin support and partial insulation from instrument-sales cyclicality. Recent sector themes — including increased demand for DNA/protein synthesis and diagnostics/AI-enabled screening — are constructive for instrument and reagent orders. Near-term market conditions have been steady without major macro shocks, leaving company fundamentals and order execution as primary drivers. Main vulnerabilities include macro-driven capex pullbacks, competitive pricing pressure from larger peers, reimbursement dynamics in diagnostics, and supply-chain or execution setbacks. Overall growth is supported by biologics and diagnostic pathway expansion, while outcomes will hinge on the pace of instrument order recovery and maintenance of consumables growth.

Key factors

  • Strong exposure to life-science research tools and clinical diagnostics with recurring revenue from consumables and reagents
  • Direct read-through from GLP-1/biologics and CRO/CDMO demand that supports instrument and reagent order momentum
  • Diagnostic and screening tailwinds (oncology/imaging-driven volume) that can raise lab-service and consumable volumes
  • Diversified product base across instruments, reagents, and clinical diagnostics reduces single-market dependence
  • Relatively stable order flow and limited macro headline shocks in the near term supporting steady trading
  • Solid operating model with high-margin consumables that help cushion instrument sales cyclicality

Risks

  • Macroeconomic slowdown leading to delayed capital spending by research labs and hospitals
  • Intense competition from larger peers (e.g., Thermo Fisher, Danaher) pressuring pricing and share gains
  • Reimbursement, payer rationalization or diagnostic-pricing pressure that could constrain clinical diagnostics revenue
  • Supply-chain disruptions or component shortages that delay instrument shipments and revenue recognition
  • Foreign-exchange volatility and exposure to international end markets that can compress reported growth
  • Execution risk on new product rollouts or integration of any M&A activities, and potential regulatory/quality issues

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for BIO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.